Artículos de revistas
Philadelphia-negative Chronic Myeloproliferative Neoplasms
Registro en:
Revista Brasileira De Hematologia E Hemoterapia. , v. 34, n. 2, p. 140 - 149, 2012.
15168484
10.5581/1516-8484.20120034
2-s2.0-84861448274
Autor
Bittencourt R.I.
Vassallo J.
Chauffaille M.L.L.F.
Xavier S.G.
Pagnano K.B.
Nascimento A.C.K.
de Souza C.A.
Chiattone C.S.
Institución
Resumen
Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although first described 60 years ago, only became the subject of interest after the turn of the millennium. In 2001, the World Health Organization (WHO) defined the classification of this group of diseases and in 2008 they were renamed myeloproliferative neoplasms based on morphological, cytogenetic and molecular features. In 2005, the identification of a recurrent molecular abnormality characterized by a gain of function with a mutation in the gene encoding Janus kinase 2 (JAK2) paved the way for greater knowledge of the pathophysiology of myeloproliferative neoplasms. The JAK2 mutation is found in 90-98% of polycythemia vera and in about 50% essential thrombocytosis and primary myelofibrosis. In addition to the JAK2 mutation, other mutations involving TET2 (ten-eleven translocation), LNK (a membrane-bound adaptor protein); IDH1/2 (isocitrate dehydrogenase 1/2 enzyme); ASXL1 (additional sex combs-like 1) genes were found in myeloproliferative neoplasms thus showing the importance of identifying molecular genetic alterations to confirm diagnosis, guide treatment and improve our understanding of the biology of these diseases. Currently, polycythemia vera, essential thrombocytosis, myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia and mastocytosis are included in this group of myeloproliferative neoplasms, but are considered different situations with individualized diagnostic methods and treatment. This review updates pathogenic aspects, molecular genetic alterations, the fundamental criteria for diagnosis and the best approach for each of these entities. 34 2 140 149 Tefferi, A., Vainchenker, W., Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies (2011) J Clin Oncol., 29 (5), pp. 573-582. , Comment in: J Clin Oncol. 2011;29(18):e564-5 Laszlo, J., Myeloproliferative disorders (MPD): Myelofibrosis, myeloscrerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia (1975) Semin Hematol., 12 (4), pp. 409-432 Vardiman, J.W., Harris, N.L., Brunning, R., The World Health Organization (WHO) classification of the myeloid neoplasms (2002) Blood., 100 (7), pp. 2292-2302. , Comment in: Blood. 2003;101(7):2895-6 Tefferi, A., Vardiman, J.W., Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms (2008) Leukemia., 22 (1), pp. 14-22. , Comment in: Leukemia. 2008;22(11):2118-9 Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes (2009) Blood, 114 (5), pp. 937-951. , Comment in: Blood. 2010;115(3):748-9 author reply 749-50 Thiele, J., Kvasnicka, H.M., Facchetti, F., Franco, V., van der Walt, J., Orazi, A., European consensus on grading bone marrow fibrosis and assessment of cellularity (2005) Haematologica., 90 (8), pp. 1128-1132 Thiele, J., Kvasnicka, H.M., Diehl, V., Standardization of bone marrow features-does it work in hematopathology for histological discrimination of different disease patterns? (2005) Histol Histopathol., 20 (2), pp. 633-644 Thiele, J., Kvasnicka, H.M., The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis (2009) Curr Hematol Malig Rep., 4 (1), pp. 33-40 Ahmed, A., Chang, C.C., Chronic idiopathic myelofibrosis: Clinicopathologic features, pathogenesis and prognosis (2006) Arch Pathol Lab Med., 130 (8), pp. 1133-1143 Chauffaille, M.L., Neoplasias mieloproliferativas: Revisão dos critérios diagnósticos e dos aspectos clínicos (2010) Rev Bras Hematol Hemoter., 32 (4), pp. 308-316 Maciel, J.F., de Lourdes Chauffaille, M., Inaoka, R.J., Colleoni, G.W., Yamamoto, M., Essential Thrombocythemia after treatment of non-Hodgkin's Lymphoma (2007) Leuk Res., 31 (11), pp. 1593-1595 Gangat, N., Tefferi, A., Thanarajasingam, G., Patnaik, M., Schwager, S., Ketterling, R., Cytogenetic abnormalities in essential thrombocythemia: Prevalence and prognostic significance (2009) Eur J Haematol., 83 (1), pp. 17-21 Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Green, A.R., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders (2005) Lancet., 365 (9464), pp. 1054-1061. , Cancer Genome Project. Erratum in: Lancet. 2005;366(9480):122 Levine, R.L., Pardanani, A., Tefferi, A., Gilliland, D.G., Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders (2007) Nat Rev Cancer., 7 (9), pp. 673-683 Barosi, G., Bergamaschi, G., Marchetti, M., Vannucchi, A.M., Guglielmelli, P., Antonioli, E., Massa, M., Barbui, T., JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis (2007) Blood., 110 (12), pp. 4030-4036. , Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Italian Registry of Myelofibrosis Kantarjian, H., Schiffer, C., Jones, D., Cortes, J., Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: Practical advice on use and interpretation of monitoring methods (2008) Blood, 111 (4), pp. 1774-1780 Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo Coco, F., Antonioli, E., Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele (2009) Blood, 114 (8), pp. 1477-1483 Tefferi, A., Lasho, T.L., Huang, J., Finke, C., Hanson, C.A., Mesa, R.A., Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival (2008) Leukemia., 22 (4), pp. 756-761 Tefferi, A., Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 (2010) Leukemia., 24 (6), pp. 1128-1138 Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel (2007) Blood., 110 (4), pp. 1092-1097. , Comment in: Blood. 2008;111(3): 1741 author reply 1742 Johansson, P., Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia (2006) Semin Thromb Hematost, 32 (3), pp. 171-173 Giuglielmelli, P., Tefferi, A., Advances in understanding and management of myeloproliferative neoplasms (2009) CA Cancer J Clin., 59 (3), pp. 171-191 Girodon, F., Bonicelli, G., Schaffer, C., Mounier, M., Carillo, S., Lafon, I., Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: A population-based study (2009) Haematologica., 94 (6), pp. 865-869 Harrison, C.N., Bareford, D., Butt, N., Campbel, P., Conneally, E., Drummond, M., Erber, W., Everington, T., Guideline for investigation and management of adults and children presenting with a thrombocytosis (2010) Br J Haematol., pp. 352-375 Lussana, F., Caberlon, S., Pagani, C., Kamphuisen, P.W., Buller, H.R., Cattaneo, M., Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review (2009) Thromb Res., 124 (4), pp. 409-417 Biergegard, G., Long-term management of thombocytosis in essential thrombocythaemia (2009) Ann Hematol., 88 (1), pp. 1-10 Landolfi, R., Gennaro, L., Prevention of thrombosis in polycythemia vera and essential thrombocythemia (2008) Haematologica., 93 (3), pp. 331-335. , Comment on: Haematologica. 2008;93(3):372-80 Finazzi, G., Ruggeri, M., Rodeghiero, F., Barbui, T., Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis (2003) Blood., 101 (9), p. 3749. , Comment on: Blood. 2001;97(4):863-6 Beer, P., Erber, W., Campbell, P., Green, A., How I treat essential thrombocythemia (2011) Blood., 117 (5), pp. 1472-1482. , Comment in: Blood. 2011;118(4):1179-80 author reply 1180-1 Kerbauy, D.M., Gooley, T.A., Sale, G.E., Flowers, M.E., Doney, K.C., Georges, G.E., Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. (2007) Biol Blood Marrow Transplant., 13 (3), pp. 355-365 Spivak, J., Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation (2010) Ann Intern Med., 152 (5), pp. 300-306 Swerdlow, S.H., (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, , International Agency for Research on Cancer., World Health Organization., Louis A. Duhring Fund. 4th ed. Lyon, France: International Agency for Research on Cancer Tefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., Pardanani, A., Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study (2011) J Clin Oncol., 29 (10), pp. 1356-1363 Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Tefferi, A., Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment (2008) Leukemia., 22 (2), pp. 437-438. , International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment (2009) Blood, 113 (13), pp. 2895-2901. , Comment in: Blood. 2010;115(3):745 author reply 745-6 Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Cazzola, M., Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis (2010) Blood., 116 (15), pp. 2857-2858 Tefferi, A., Siragusa, S., Hussein, K., Schwager, S.M., Hanson, C.A., Pardanani, A., Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype (2010) Am J Hematol., 85 (1), pp. 14-17. , Comment in: Am J Hematol. 2010;85(1):4-5 Caramazza, D., Begna, K.H., Gangat, N., Vaidya, R., Siragusa, S., van Dyke, D.L., Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients (2011) Leukemia., 25 (1), pp. 82-88 Mesa, R.A., Nagorney, D.S., Schwager, S., Allred, J., Tefferi, A., Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic (2006) Cancer., 107 (2), pp. 361-370 Elliott, M.A., Tefferi, A., Splenic irradiation in myelofibrosis with myeloid metaplasia: A review (1999) Blood Rev., 13 (3), pp. 163-170 Ballen, K.K., Shrestha, S., Sobocinski, K.A., Zhang, M.J., Bashey, A., Bolwell, B.J., Outcome of transplantation for myelofibrosis (2010) Biol Blood Marrow Transplant., 16 (3), pp. 358-367 Verstovsek, S., Kantarjian, H., Mesa, R.A., Pardanani, A.D., Cortes-Franco, J., Thomas, D.A., Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis (2010) N Engl J Med., 363 (12), pp. 1117-1127. , Comment in: N Engl J Med. 2010 363(12): 1180-2 N Engl J Med. 2010;363(25):2464 author reply 2464-5 discussion 2465 Pardanani, A., Gotlib, J.R., Jamieson, C., Cortes, J.E., Talpaz, M., Stone, R.M., Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis (2011) J Clin Oncol., 29 (7), pp. 789-796. , J Clin Oncol. 2011;29(7):781-3 Vaquez, H., Sur une forme spéciale de cyanose s'accompgnant d'hyperglobulie excessive et persistant (1892) Comptes rendus de La Société de Biologie, 44, pp. 384-388. , Paris Osler, W., Chronic cyanosis with polycythemia and enlarged spleen: A new clinical entity (2008) Am J Med Sci., 335 (6), pp. 411-417. , Comment in: Am J Med Sci 2008;335(6):418-9 Berlin, N.I., Diagnosis and classification of the polycythemias (1975) Semin Hematol., 12 (4), pp. 339-351 Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., A gain-of-function mutation of JAK2 in myeloproliferative disorders (2005) N Engl J Med., 352 (17), pp. 1779-1790. , Comment in: N Engl J Med. 2005;353(13):1416-7 author reply 1416-7 N Engl J Med. 2005;352(17):1744-6 Passamonti, F., Rumi, E., Pietra, D., della Porta, M.G., Boveri, E., Pascutto, C., Relation between JAK2(V617F) mutation status, granulocyte activation and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders (2006) Blood., 107 (9), pp. 3676-3682 Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., JAK2 exon 12 mutations in polycythemia vera and idiopathic eritrocytosis (2007) N Engl J Med., 356 (5), pp. 459-468. , Comment in: N Engl J Med. 2007;356(5):444-5 McMullin, M., Reilly, J.T., Campbell, P., Bareford, D., Green, A., Harrison, C., Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis (2007) Br J Haematol, 138, pp. 812-823 Crisà, E., Venturino, E., Passera, R., Prina, M., Schinco, P., Borchiellini, A., A retrospective study on 226 polycythemia vera patients: Impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and nonalkylating drugs (2010) Ann Hematol., 89 (7), pp. 691-699 Barbui, T., Carobbio, A., Rambaldi, A., Finazzi, G., Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor? (2009) Blood., 114 (4), pp. 759-763 Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Response criteria for essential thrombocythemia and polycythemia vera: Result of a European LeukemiaNet consensus conference (2009) Blood., 113 (20), pp. 4829-4833 Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Tefferi, A., Philadelphia-Negative Classical Myeloproliferative Neoplass: Critical Concepts and Management Recommendations from European Leukemianet (2011) J Clin Oncol., 29 (6), pp. 761-770. , European LeukemiaNet. Comment in: J Clin Oncol. 2011;29(18):e564-5 Rambaldi, A., Dellacasa, C.M., Salmoiraghi, S., A phase 2 A study of the histone-deacetylase inhibitor in patients with JAK2V617F positive myeloproliferative neoplasms. {abstract} (2008) Blood, 112, p. 100. , (não localizada) Chauffaille, M.L.L.F., Neoplasias mieloproliferativas: Revisão dos critérios diagnósticos e dos aspectos clínicos (2010) Rev Bras Hematol. Hemoter, 32 (4), pp. 308-316 Tefferi, A., Patnaik, M.M., Pardanani, A., Eosinophilia: Secondary, clonal and idiopatic (2006) Br J Haematol., 133 (5), pp. 468-492 Fletcher, S., Bain, B., Diagnosis and treatment of hypereosinophilic syndromes (2007) Curr Opin Hematol., 14 (1), pp. 37-42 Metcalfe, D.D., Mast cells and mastocytosis (2008) Blood., 112 (4), pp. 946-956